Tumor mutational burden, as measured by exome or panel sequencing of tumor tissue (tTMB) or blood (bTMB), has been identified as a potential predictive biomarker for treatment benefit in patients with various cancer types receiving immunotherapy targeting checkpoint pathways. However, significant variability in TMB measurement has been reported due to differences in preanalytical and laboratory methods, panel size, number of genes covered, and bioinformatics pipelines.
Reference standards have been proposed and evaluated for tTMB analysis by the Friends of Cancer Research TMB Harmonization Consortium to enable standardization across different NGS panel providers and to determine the correlation of panel-TMB scores with WES-TMB scores. Reference standards for bTMB may be even more important given the unique challenges and higher sensitivity required for bTMB assays.
This datasheet from LGC SeraCare provides details about the blood TMB assessments for Seraseq Blood TMB Mix Score 7, 13, 20, 26 reference materials as determined using the TruSight Oncology 500 ctDNA panel.
Find the accompanying poster for this data sheet from SeraCare here
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences